RxDoctor Payments Data

Charles Ford, MD

Otolaryngology · Boone, NCNPI 1164481727

Payments from drug & device makers

$2,151in general payments, 2019–2025

Across 84 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$522
  • Sanofi$387
  • Alk-abello, Inc$196
  • Stryker$194
  • Optinose US, Inc.$177
  • ARS Pharmaceuticals Operations, Inc.$123
  • plus $551 from 13 others

What the payments were for

  • Food & beverage$2,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,151 in reported general payments places this provider in the 65th percentile of 362 otolaryngology providers in North Carolina.

See all otolaryngology providers in North Carolina

Medicare billing

Part B allowed, 2024
$201,043
Medicare patients
589
Services billed
4,928

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SynthroidLevothyroxine Sodium205$12,552
SymbicortBudesonide/Formoterol Fumarate20$9,879
Ipratropium Bromide293$9,524
Famotidine732$8,369
Epinephrine32$6,655
Cevimeline Hcl28$4,303
Mometasone Furoate13$3,616
Pilocarpine Hcl82$3,115
Omeprazole303$2,940
Azelastine Hcl78$2,542
Gabapentin261$2,372
Montelukast Sodium361$2,203
Cyproheptadine Hcl92$2,108
Budesonide15$1,923
Olopatadine Hcl11$1,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$62$12,552205 claims
AstraZenecaSymbicort$28$9,87920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 362 otolaryngology providers in North Carolina.

Other otolaryngology in Boone

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →